Dimerix Limited Announces Management Changes
strategic, scientific and operational aspects of product development. In her most recent role, Nina was Commercial Director of Acrux Limited, where she was responsible for the strategic identification, development and maintenance of commercial partnerships globally, the intellectual property portfolio and investor relations. Whilst at Acrux she had a lead role in multiple commercial transactions with global pharmaceutical companies that collectively have netted over $300 million in revenue to date, and she prosecuted several complex US-based intellectual property matters. Prior to that she was the Director of Commercialisation & IP for Immuron. As previously advised, with this appointment, Kathy Harrison will now transition into the COO role allowing focus on the important task of executing clinical programs for which she has demonstrated enormous talent.